Jupiter Neurosciences, Inc. Receives Nasdaq Delisting Notices: What Investors Need to Know

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) has filed a Form 8-K current report disclosing that, on February 26, 2026, the company received two written notices from the Listing Qualifications Department of Nasdaq Stock Market LLC. These notices are significant and may be price-sensitive, as they relate to the possible delisting of the company’s common stock from the Nasdaq Capital Market.

Key Points from the Report

• Delisting Notices Received: Jupiter Neurosciences was notified by Nasdaq that the listing of its common stock (par value \$0.0001 per share) is at risk due to non-compliance with the Nasdaq Listing Rules.
• No Immediate Effect: The notices do not have an immediate effect on the listing status. The company’s common stock will continue to trade uninterrupted on the Nasdaq Capital Market under the ticker symbol “JUNS”.
• Deficiencies Identified: The report indicates that the company is out of compliance with certain continued listing standards, specifically minimum bid price and Market Value of Listed Securities (MVLS). These are critical metrics for maintaining a Nasdaq listing.
• Company Response: Jupiter Neurosciences states its intention to actively monitor its minimum bid price and MVLS. The company is considering options to resolve these deficiencies, including the possibility of a reverse stock split—a move often used to increase share price and regain compliance.
• No Assurance of Continued Listing: The company cautions investors that there is no assurance it will be successful in maintaining its Nasdaq listing. This uncertainty could impact investor sentiment and share price.
• Emerging Growth Company Status: Jupiter Neurosciences identifies itself as an emerging growth company, which may affect its financial reporting and compliance obligations.
• Regulation FD Disclosure: The company highlights that, in addition to SEC filings, it may use its corporate website (https://jupiterneurosciences.com) and social media channels (X/Twitter: @jupiterneuro, Instagram: @Nugevia) to communicate material information. Investors are encouraged to monitor these channels for updates.

Potential Impact on Shareholders

• Price Sensitivity: The risk of delisting from Nasdaq is a highly price-sensitive event. If the company is unable to regain compliance, the shares could be transferred to an over-the-counter (OTC) market, which typically results in reduced liquidity and possibly lower share value.
• Reverse Stock Split: If implemented, a reverse stock split would reduce the number of outstanding shares, potentially increasing the price per share but not the underlying value. This can signal distress and may affect investor confidence.
• Investors Should Monitor for Updates: Shareholders should closely follow all company communications, including SEC filings, press releases, and social media postings, for further developments regarding its Nasdaq listing status.
• Forward-Looking Statements: The company makes forward-looking statements regarding its plans to regain compliance. Actual results may differ materially due to risks and uncertainties.

Summary

Jupiter Neurosciences, Inc. is facing a crucial challenge regarding its Nasdaq listing. The receipt of delisting notices is an important event for investors and could significantly affect the value and liquidity of JUNS shares. While the stock continues to trade on Nasdaq for now, the company’s efforts to regain compliance—including consideration of a reverse stock split—are critical and merit close attention. There is no guarantee the company will succeed, and shareholders should be prepared for potential volatility.

Disclaimer

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. The information herein is based on company filings and public disclosures. Investors should conduct their own due diligence and consider consulting a qualified financial advisor before making investment decisions. Forward-looking statements are subject to risks and uncertainties. Past performance is not indicative of future results.

View JUPITER NEUROSCIENCES, INC. Historical chart here